Arcus Biosciences EBIT

The latest EBIT for RCUS is $-440M as of June 2026. That compares with $-330M in the prior-year period — down 33.7% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Arcus Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, RCUS's EBIT moved from $-330M to $-440M — a 33.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Arcus Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, RCUS currently prints $-440M for EBIT, while the sector average sits near $23B. That is roughly 101.9% below the sector mean. Large gaps often invite a closer look at Arcus Biosciences's growth, margins, and balance sheet.

A EBIT figure of $-440M for RCUS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting RCUS's EBIT ($-440M), review year-over-year change from $-330M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.